Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials
Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL). <b>Clinical Trials Registration.</b> NCT02831673/NCT02831764; NCT03945981.
Authors
- Richard Grove
- Roberto Ortiz (ORCID: https://orcid.org/0009-0006-1036-3085)
- José Ramón Arribas (ORCID: https://orcid.org/0000-0002-7410-9450)
- Michelle Kisare (ORCID: https://orcid.org/0009-0004-9413-5295)
- Mark Underwood (ORCID: https://orcid.org/0000-0002-6803-2346)
- Chris M. Parry (ORCID: https://orcid.org/0000-0002-3295-0436)
- Charlotte-Paige Rolle (ORCID: https://orcid.org/0000-0002-6444-2225)
- V. Paul DiMondi
- Bryn Jones (ORCID: https://orcid.org/0000-0001-9296-367X)
Institutions
- Orlando Health (US)
- ViiV Healthcare (Spain) (ES)
- Geological Society of London (GB)
- Hospital Universitario La Paz (ES)
- ViiV Healthcare (United Kingdom) (GB)
- Hospital La Paz Institute for Health Research (ES)
- Centro de Investigación Biomédica en Red (ES)
- Orlando Immunology Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/ofid/ofaf135
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79